Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics Inc (QNCX) is a preclinical-stage biopharmaceutical company pioneering bone-targeted therapies for rare diseases and fractures. This page aggregates official news and press releases to help stakeholders track scientific advancements, strategic partnerships, and regulatory developments.
Key Resources: Access timely updates on clinical research milestones, financial disclosures, and leadership announcements. Our curated collection ensures investors and researchers stay informed about QNCX's innovative drug delivery platform and its potential market impact.
Content Includes: Earnings reports, preclinical trial updates, intellectual property filings, and collaborations within the regenerative medicine sector. All materials are sourced directly from company communications to ensure accuracy.
Bookmark this page for streamlined access to Quince Therapeutics' latest developments. Check regularly for updates on their bone-targeting platform and progress toward addressing unmet medical needs.
Quince Therapeutics (Nasdaq: QNCX) has received Fast Track designation from the U.S. FDA for its EryDex System, intended for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric disease. The EryDex System uses Quince's proprietary AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) in a patient’s red blood cells, aiming to mitigate the side effects of chronic corticosteroid treatments. Fast Track status highlights the severe unmet medical need for A-T, which affects roughly 10,000 patients in the U.S., U.K., and EU4 countries. A prior Phase 3 study of EryDex demonstrated encouraging efficacy and safety results. Quince is currently enrolling participants for its pivotal Phase 3 NEAT clinical trial under a Special Protocol Assessment (SPA) agreement with the FDA.
Quince Therapeutics, a late-stage biotech company, provided updates on its development pipeline and financial results for Q1 2024. The company is focusing on advancing their lead asset, EryDex, for ataxia-telangiectasia and Duchenne muscular dystrophy. They secured regulatory approvals for their pivotal Phase 3 NEAT clinical trial and are on track for enrollment. The potential market opportunity for their A-T treatment is estimated at over $1 billion globally. Quince is also evaluating other indications for EryDex and exploring strategic partnerships to support their pipeline expansion. Financially, they reported cash reserves of $67.8 million for Q1 2024 and expect to fund operations through 2026.
Quince Therapeutics, Inc. (Nasdaq: QNCX) will present at The Citizens JMP Life Sciences Conference to discuss their innovative drug delivery technology for rare diseases. The presentation by Quince's CEO and CMO will be available via live webcast on May 13, 2024.
FAQ
What is the current stock price of Quince (QNCX)?
What is the market cap of Quince (QNCX)?
